… Systemic sclerosis (SSc) or scleroderma is a complex autoimmune disease characterized
by widespread vasculopathy, multi-systemic excessive fibrosis, and autoantibody production. …

… the therapeutic opportunity window(s). So far, treatment of SSc has been applied to patients
fulfilling the 1980 ACR classification criteria for SSc [19], which by and large are based on …

… Systemic sclerosis (SSc), also known as systemic scleroderma, is a collagenosis encumbered
by a chronic inflammatory process with autoimmune determinism. The pathogenesis of …

… Abstract: Pulmonary arterial hypertension (PAH) is an important cause of death in systemic
sclerosis (SSc), despite the improvement of therapies. An early diagnosis and the use of …

… trials in diffuse cutaneous systemic sclerosis will be proposed. We will also discuss selected
therapeutic pathways currently under investigation in systemic sclerosis that still lack clinical …

… Systemic sclerosis (SSc) is a multifaceted systemic autoimmune disease. Its pathogenesis
classically recognizes three different main mechanisms, that is, microvascular damage, …

… Fibroblast activation and myofibroblast transdifferentiation underlie multiple organ fibrosis
in systemic sclerosis (SSc). Transforming growth factor-β (TGFβ) is centrally involved in …

… Therapeutic goals in systemic sclerosis (SSc) include minimization of damage from early
inflammation and autoimmunity, restoration of vascular homeostasis, promotion of repair of …

… therapeutic strategies and new medications under development for the treatment of systemic
sclerosis … first-line therapies for the treatment of cutaneous sclerosis in patients with dcSSc, …

… We discuss herein novel insights into the pathogenesis of fibrotic diseases, using
systemic sclerosis (SSc) as an example of a multisystem idiopathic disorder. We set a strong …